OCS — Oculis Holding AG catalysts
Next verified catalyst
2026-12-01 — A Clinical Study Evaluating Licaminlimab for Dry Eye Disease · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12 (month) in 4mo
ESTIMATED |
READOUT
A Clinical Study Evaluating Licaminlimab for Dry Eye Disease
Phase 2/3 · Dry Eye Disease (DED) |
OCS Oculis Holding AG | Artificial Tear Run-in, licaminlimab, Ve |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|